Biodesix, Inc. (BDSX) Posts Fourth Quarter Loss, Surpasses Revenue Projections

Biodesix, Inc. (BDSX) Reports Smaller-Than-Expected Quarterly Loss

Biodesix, Inc. (BDSX) announced a quarterly loss of $0.49 per share, which was significantly better than the consensus estimate of a $1.05 loss. In comparison, the company reported a loss of $1.20 per share in the same period last year. These results exclude one-time items.

This performance reflects a positive earnings surprise of 53.33%. In the previous quarter, Biodesix was anticipated to post a loss of $1.60 per share but instead reported a loss of $1.16, resulting in a 27.5% earnings beat.

Looking at the past four quarters, Biodesix has exceeded analysts’ EPS expectations twice.

For the quarter ending December 2025, Biodesix, a member of the Medical Services sector, generated $28.76 million in revenue, surpassing the consensus estimate by 14.11%. This marks an increase from $20.43 million in revenue during the same quarter last year. Over the last year, the company has outperformed revenue estimates in three out of four quarters.

The immediate impact on Biodesix’s stock price will likely depend on management’s insights and guidance shared during the earnings call.

Since the start of the year, Biodesix shares have climbed approximately 90.2%, compared to a 1.5% gain for the S&P 500.

What Lies Ahead for Biodesix?

Although Biodesix has delivered strong returns so far this year, investors are now considering the company’s future prospects.

One key factor in evaluating what’s next for the stock is the company’s earnings outlook, which includes both current consensus estimates for upcoming quarters and any recent changes to those forecasts.

Research indicates that short-term stock price movements are closely linked to trends in earnings estimate revisions. Investors can monitor these changes themselves or use established tools like the Zacks Rank, which leverages earnings estimate trends to rate stocks.

Prior to this earnings announcement, analyst estimate revisions for Biodesix were mixed. While these may shift following the latest results, the stock currently holds a Zacks Rank #3 (Hold), suggesting it is expected to perform in line with the broader market.

It will be important to watch how earnings and revenue estimates for the next quarters and the current fiscal year evolve. Presently, analysts project an EPS of -$1.17 on $23.5 million in revenue for the next quarter, and an EPS of -$3.75 on $103.9 million in revenue for the full year.

Investors should also consider the broader industry outlook, as it can significantly influence individual stock performance. The Medical Services sector currently ranks in the bottom 39% of over 250 industries tracked by Zacks. Historically, the top half of Zacks-ranked industries have outperformed the lower half by more than two to one.

Industry Comparison: Sonida Senior Living (SNDA)

Sonida Senior Living (SNDA), another company in the Medical Services space, has not yet released its results for the quarter ending December 2025.

Sonida is expected to report a quarterly loss of $1.17 per share, reflecting a 41% year-over-year decline. The consensus EPS estimate for the quarter has remained unchanged over the past month.

Revenue for Sonida Senior Living is projected at $88.89 million, representing a 3.3% decrease from the same quarter last year.

Is Biodesix, Inc. (BDSX) a Good Investment?

Thinking about investing in Biodesix, Inc. (BDSX)?

Since 1978, Zacks Investment Research has provided investors with independent research and powerful tools. Over the past 25 years, the Zacks Rank stock-rating system has delivered an average annual return of 24.08%, more than doubling the S&P 500’s performance during the period from January 1, 1988, through May 6, 2024.